San Antonio Breast Cancer Symposium

December 2011
BioWorld Today;12/9/2011, Vol. 22 Issue 237, p5
The article deals with the interim data presented by Generex Biotechnology Corp. at the 2011 San Antonio Breast Cancer Symposium from its continuing Phase II study of the li-Key hybrid-based HER2/neu peptide vaccine in HER2-expressing breast cancer patients.


Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;2/13/2014, Vol. 25 Issue 30, p7 

    This section offers news briefs on clinical studies by biopharmaceutical companies as of February 13, 2014. Generex Biotechnology Corp. reported results from a phase II study of AE37 cancer vaccine for preventing relapse in breast cancer patients. Omeros Corp. reported that OMS824 achieved...

  • Generex awarded $224,000 to develop novel breast cancer vaccine.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p7 

    Reports that Generex Biotechnology Corp. has received a small Business Innovative Research award from the National Cancer Institute to develop a T-helper cell breast cancer vaccine. Vaccine's stimulation of the immune system to segments of HER-2/neu, a dominant antigen found on cancer cells;...

  • Generex subsidiary enters breast cancer vaccine collaboration.  // PharmaWatch: Cancer;November 2004, Vol. 3 Issue 11, p15 

    Reports that Generex Biotechnology Corporations's wholly owned subsidiary, Antigen Express, has entered into a collaborative research and development agreement to advance breast cancer vaccine efforts. Involvement of the Uniformed Services of the Health Sciences (USU), the Henry M. Jackson...

  • Research Update.  // PharmaWatch: Biotechnology;Mar2007, Vol. 6 Issue 3, p5 

    The article reports on developments on the research and trials of various drugs. Generex Biotechnology Corp. has entered into a phase II trial, utilizing its peptide vaccine in breast cancer patients, in cooperation with the U.S. Military Cancer Institute's Clinical Trials Group. GenVec Inc. is...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

  • AACR Roundup.  // BioWorld Today;4/5/2011, Vol. 22 Issue 65, p8 

    The article focuses on the study data presented by Generex Biotechnology Corp. at the annual meeting of the American Association for Cancer Research (AACR) on the effect of a peptide vaccine on a subgroup of CD4-positive cells can suppress immune responses.

  • ASCO 2013.  // BioWorld Today;6/3/2013, Vol. 24 Issue 105, p7 

    The article discusses data for li-Key modified HER2 peptide vaccine presented by Generex Biotechnology Corp. at the American Society of Clinical Oncology (ASCO) meeting held in Chicago, Illinois in June 2013.

  • RXi Acquisition of Apthera Builds Breast Cancer Assets. Schaffer, Catherine // BioWorld Today;4/1/2011, Vol. 22 Issue 63, p1 

    The article reports on the acquisition of Apthera Inc. of Scottsdale, Arizona by RXi Pharmaceuticals Corp. of Worcester, Massachusetts. The definitive merger agreement between the companies requires RXi to issue roughly 4.8 million shares of common stock to the shareholders of Apthera. The...

  • Breast Cancer News Headlines July 15, 2003-- August 14, 2003.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p6 

    Lists the breast cancer news headlines of the "Datamonitor" journal from July 15 to August 14, 2003. Inhibition of the growth of tumor metastases by Peregrine's vascular targeting agent; CancerVax's studies on humanized antibodies; Generex's grant to develop breast cancer vaccine; Roche's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics